外周血造血干细胞移植治疗血液病125例疗效分析

张培娇; 刘林

doi:10.13201/j.issn.1004-2806.2012.06.009

外周血造血干细胞移植治疗血液病125例疗效分析

张培娇,
刘林^,

- 重庆医科大学附属第一医院血液内科(重庆, 400016)

详细信息

通讯作者: 刘林,E-mail:liul7776@yahoo.com

中图分类号: R617

收稿日期: 2012-02-24

Effectiveness of peripheral blood stem cells transplantation in 125 patients with hematological disorders

ZHANG Peijiao,
LIU Lin^,

- Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China

More Information

Corresponding author: LIU Lin, E-mail: liul7776@yahoo.com

Received Date: 24 February 2012

摘要

摘要: 目的:评价外周血造血干细胞移植(PBSCT)治疗血液病的临床疗效及并发症。方法:回顾性分析接受HSCT的125例血液病患者的临床资料。结果:123例患者成功获得造血重建,中性粒细胞计数≥0.5×10⁹ /L平均时间为11.5 d,血小板计数≥20×10⁹ /L平均时间为14.8 d;allo-HSCT组急性移植物抗宿主病(aGVHD)发生率为12.8%(6/47),慢性移植物抗宿主病(cGVHD)发生率为23.4%(11/47),移植相关病死率4.2%(2/47)。中位随访时间12(0~58)个月,复发率在自体移植和异基因移植患者中分别为26.9%(21/78)和10.6%(5/47),总复发率为20.8%。auto-HSCT组和allo-HSCT组总生存率(OS)、无病生存率(DFS)Meier曲线差异无统计学意义。结论:HSCT造血重建快,移植相关并发症较少,是一种安全而有效的治疗方法。
- 造血干细胞移植 /
- 血液病 /
- 总生存率 /
- 无病生存率
Abstract: Objective:To evaluate clinical effectiveness and complications of hematopoietic stem cell transplantation(HSCT)in the treatment of hematological disorders.Method:The clinical data from 125 patients with hematologic diseases who received PBSCT were collected.Result:Hemapoietic reconstruction was successful in all patients.The average time was 11.5 d for neutrophil reconstruction(≥0.5×10⁹ /L)and 14.8 d for platelet reconstruction(≥20×10⁹ /L).The incidence of acute and chronic graft-versus-host-disease(aGVHD and(cGVHD)in allo-HSCT was 12.8% and 23.4% respectively.Median follow up time was 11 months.The incidence of disease relapse was 26.9% in auto-HSCT group and 10.6% in Allo-PBSCT group.The total relapse rate was 20.8%.The Kaplan-Meier curve of the overall survival(OS),disease free survival(DFS)showed no significant difference between auto-HSCT and allo-HSCT.Conclusion:PBSCT can provide rapid hematopoietic reconstitution.It is a better choice for the cure of malignant hematologic diseases.
- peripheral blood stem cell transplantation /
- hemato logic disease /
- overall survival /
- disease free survival

HTML全文

参考文献(8)

[1]	韩伟,陆道培,黄晓军,等.HLA配型不合造血干细胞移植GIAC方案100例临床分析[J].中华血液学杂志,2004,25(8):7-11.
[2]	BENSINGER W I,MARTIN P J,STORER B,et al.Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers[J].N Engl J Med,2001,344:175-181.
[3]	COUBAN S,SIMPSON D R,BARNETTM J,et al.A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants form yeloid malignancies[J].Blood,2002,100:1525-1531.
[4]	SCOTT M A,GANDHI M K,JESTICE H K,et al.A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood pro genitor cell transplantation:a case controlled study [J].Bone Marrow Transplant,1998,22:273-276.
[5]	ROSENBECK L L,SRIVASTAVA S,KIEL P J.Peripheral blood stem cell mobilization tactics [J].Ann Pharmacother,2010,44:107-116.
[6]	GREWAL S S,BARKER J N,DAVIES S M,et al.Unrelated donor hematopoietic cell transplantation:marrow or umbilical cord blood[J]? Blood,2003,101:4233-4244.
[7]	ORTEGA M,ROVIRA M,ALM ELA M,et al.Bacterial and fungal blood stream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000[J].Ann Hemartol,2005,84:40-47.
[8]	LEUNG A Y,YUEN K Y,KWONG Y L,et al.Polyoma BK virus and haemorrhagic cystitis in haematopoietie stem cell transplantation:a changing paradigm[J].Bone Marrow Transplant,2005,36:929-937.